Indoco Remedies Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/75ek01rnzrai6qnf0wjey44h.pdf

Key Takeaways


India Business: The Core Engine

Aditi Panandikar: "As I said earlier, as an organization, you are trying to make major strategic changes in keeping with market conditions, then sometimes you have to take turns, sometimes U-turn, sometimes right-angle turn. And while taking turns, it's not possible to keep the speed intact."

U.S. Business: Waiting on Goa Plant 2

Aditi Panandikar: "But most of the plants related corrections would get completed in the second quarter. So we expect from Q3 to be able to have consistent supply."

Margin Walk: Compression and Recovery Path


Europe: Building Beyond Paracetamol


Capex and Capacity: The Payback Question

Aditi Panandikar: "Let me tell you very clearly that our strategy is correct. The decisions we made are also correct. Although some of the decisions have come in at a time when there have been massive headwinds that we had from the markets, whether regulatory or otherwise, and therefore, there has been postponement in getting returns from them."

Emerging Markets and Other Businesses


Guidance & Commitments

CommitmentSpecificsTimeline
Plant corrections completionMost plant-related corrections completed, enabling consistent supplyEnd of Q2 FY25
U.S. revenue recoveryConsistent U.S. supply and strong revenuesFrom Q3 FY25
EBITDA marginMinimum 15%Q3 FY25
EBITDA marginMinimum 15% for full year; Q4 stronger than Q3FY25
Other expensesStabilize at ₹110 cr to ₹120 cr per quarterGoing forward
CapexMaintain at ₹250 crFY25
U.S. growth30% CAGROver next 2 years
Emerging markets growth18% to 20% CAGRNext couple of years
API businessMore than doubleGoing forward
API internal/external ratioFlip from 60:40 to 40:60 (sell ~60%)From this year
Cumulative capex paybackMinimum 2 yearsFrom here on
Remediation costsContinue at ~₹4 cr per quarterAt least one more quarter
Incremental debtBorrow close to another ₹100 cr beyond cash flowUnspecified

Key Metrics

MetricQ1 FY25
Net revenue₹394.2 cr, degrew 4.6% YoY vs ₹413.2 cr
EBITDA margin13.1% at ₹51.6 cr, vs 15.2% at ₹62.9 cr YoY
PAT margin3.8% at ₹15 cr, vs 6.3% at ₹25.9 cr YoY
EPS₹1.62, vs ₹2.81 same quarter last year
Domestic formulation revenue₹200.2 cr, vs ₹213 cr YoY
International formulation revenue₹157.1 cr, vs ₹159.7 cr YoY
US business revenue₹48.7 cr, vs ₹51.2 cr YoY; short of close to ₹20 cr in supply
Europe revenue₹75.4 cr, vs ₹79.4 cr YoY
Emerging markets revenue₹29.8 cr, vs ₹25.3 cr YoY
API business revenue₹31.2 cr, vs ₹35.7 cr YoY
AnaCipher CRO and Indoco Analytical Solutions revenue₹5.7 cr, grew ~20% YoY vs ₹4.8 cr
Remediation costs~₹4 cr per quarter, same run rate maintained
Short-term debt~₹350 cr
Long-term debt~₹250 cr (term loan ₹250 cr, other ₹284 cr)
D2C Oral Care revenue~₹25 cr from two variants